Address
Email address
Phone number
Website
PET/SPECT precursors, reference standards and auxiliary reagents in GMP grade.
Name
PharmaSynth AS
Registry code
11044101
VAT number
EE100940196
Type
AS - Joint Stock Company
Status
Registered
Foundation date
29.06.2004 (20)
Financial year
01.01-31.12
Capital
57 180.00 €
Activity
21201 - Manufacture of pharmaceutical preparations
635 352 €
145 484 €
23%
2 726 €
(estimate is approximate)
896 244 €
7
Submitted
No tax arrears
16%
15%
Owner | Representative | Beneficial owner | Roles | |
---|---|---|---|---|
Heli Väärtnõu-Järv 11.06.1959 (65) | 11% - 6 180.00 EUR | - | - | FounderBoard memberShareholder |
SILLAMATSI MEDICAL OÜ 10913017 | 49% - 28 140.00 EUR | - | - | FounderShareholder |
Pirkko-Irene Penttilä-Hiltunen 11.01.1955 (69) | - | Board member | - | Founder |
Jukka Veli Hiltunen 10.11.1954 (70) | - | - | Direct ownership | Founder |
Olavi Loog 27.08.1969 (55) | - | - | - | Board member |
OÜ EDUSOFT 10769658 | - | - | - | Founder |
Jaak Järv 05.11.1948 (76) | - | - | - | FounderChairman of the board |
2019 05.10.2020 | 2020 05.08.2021 | 2021 02.03.2023 | 2022 21.06.2023 | 2023 26.06.2024 | |
---|---|---|---|---|---|
Total Revenue | 319 371 € | 444 406 € | 510 772 € | 475 618 € | 635 352 € |
Net profit (loss) for the period | 42 880 € | 199 141 € | 247 819 € | 121 436 € | 145 484 € |
Profit Margin | 13% | 45% | 49% | 26% | 23% |
Current Assets | 213 484 € | 398 964 € | 588 770 € | 635 684 € | 783 422 € |
Fixed Assets | 25 598 € | 38 269 € | 90 310 € | 197 667 € | 157 357 € |
Total Assets | 239 082 € | 437 233 € | 679 080 € | 833 351 € | 940 779 € |
Current Liabilities | 45 479 € | 55 728 € | 49 756 € | 82 591 € | 44 535 € |
Non Current Liabilities | 11 239 € | 0 € | - | - | - |
Total Liabilities | 56 718 € | - | - | - | - |
Share Capital | 60 908 € | 60 908 € | 60 908 € | 60 908 € | 57 180 € |
Equity | 182 364 € | 381 505 € | 629 324 € | 750 760 € | 896 244 € |
Employees | 8 | 7 | 7 | 7 | 7 |
Turnover | State taxes | Labor taxes and payments | Employees | |
---|---|---|---|---|
2024 Q1 | 139 706.86 € | 31 247.92 € | 32 989.43 € | 8 |
2023 Q4 | 74 760 € | 30 655.78 € | 32 095.88 € | 8 |
2023 Q3 | 189 319.51 € | 30 190.54 € | 31 856.61 € | 8 |
2023 Q2 | 144 446.36 € | 34 124.62 € | 36 060.7 € | 8 |
2023 Q1 | 194 810.66 € | 30 068.21 € | 31 743.36 € | 8 |
2022 Q4 | 136 055.56 € | 24 294.54 € | 25 555.64 € | 8 |
2022 Q3 | 108 932.07 € | 19 035.63 € | 19 929.45 € | 8 |
2022 Q2 | 112 649.3 € | 16 704.07 € | 15 587.78 € | 8 |
2022 Q1 | 96 840.74 € | 19 011.71 € | 20 014.68 € | 7 |
2021 Q4 | 146 515.77 € | 16 656.35 € | 17 566.97 € | 8 |
2021 Q3 | 109 604.25 € | 16 646.19 € | 17 671.99 € | 8 |
2021 Q2 | 137 043.77 € | 14 379.25 € | 15 141.82 € | 8 |
2021 Q1 | 137 042.39 € | 20 087.77 € | 21 365.31 € | 8 |
2020 Q4 | 58 124.73 € | 11 993 € | 12 792.19 € | 8 |
2020 Q3 | 82 335 € | 11 905.82 € | 12 671.89 € | 8 |
2020 Q2 | 70 810.61 € | 11 233.75 € | 11 943.8 € | 7 |
2020 Q1 | 144 400.94 € | 19 608.94 € | 19 640.49 € | 7 |